News

New tool interprets the raw data of whole exome tumor sequencing and then matches the cancer’s unique genetics to FDA-approved targeted treatments.

Study using patient-derived cells within human extracellular matrix (ECM) to replicate heterogeneous tumor microenvironments aims to improve breast and ovarian cancer treatment by decreasing anti-cancer drug failure rates on a large-scale.

Vaccine protects against multiple strains of both seasonal and pandemic H1N1 influenza.

Company has announced partnership with Andros Men's Health Clinic to offer the SelectMDx(TM) for Prostate Cancer test to their patients.

Company has announced collaboration with Principia Biopharma to use Guardant360® for monitoring patient response and tumor evolution in FGFR inhibitor trials.

Company has entered a strategic license and development agreement with BioChain on novel, blood-based lung cancer test for China.

Company has created challenges in the API manufacturing industry to exhibit high quality and regulatory compliance best practice, and to continually increase confidence within the marketplace.

Qlucore software enables researchers to more easily study the genetic influences behind childhood cancer.

Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.

Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.